A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

2004552 citationsJournal Article

Authors

John M. Kirkwood · UPMC Hillman Cancer Center

Judith Manola · Dana-Farber Cancer Institute

Joseph G. Ibrahim · University of North Carolina at Chapel Hill

Vernon K. Sondak · University of Michigan–Ann Arbor

Marc S. Ernstoff · Dartmouth–Hitchcock Medical Center

Uma Rao · UPMC Hillman Cancer Center

Abstract

In patients with high-risk resected melanoma, HDI is effective adjuvant therapy with strong evidence for improved RFS and evidence for moderate improvement in OS based on two prospective randomized studies but not the pooled analysis. Analyses of predictors of relapse and response are now needed to improve the therapeutic value of this modality.

Topics & Keywords

Cutaneous Melanoma Detection and Management Immunotherapy and Immune Responses CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 10, Issue 5, pp. 1670-1677

DOI: 10.1158/1078-0432.ccr-1103-3

Field-Weighted Citation Impact: 16.72